Display Settings:

Format

Send to:

Choose Destination
    J Pediatr. 2008 Apr;152(4):582-4.

    Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

    Source

    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

    Abstract

    5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD). 2 pre-pubertal subjects experienced >6% BMD decreases. 1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted.

    PMID:
    18346519
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2390888
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk